View in EDS

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.

Saved in:
Bibliographic Details
Title: Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
Authors: Shen S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Teysir J; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Safonov A; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bromberg M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chen Y; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ahmed M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Razavi P; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical Center, New York, NY, USA., Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, NY, USA. jhaverik@mskcc.org.; Weill Cornell Medical Center, New York, NY, USA. jhaverik@mskcc.org.
Source: Breast cancer research : BCR [Breast Cancer Res] 2026 Jan 31; Vol. 28 (1). Date of Electronic Publication: 2026 Jan 31.
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41620612
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shen+S%22">Shen S</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Teysir+J%22">Teysir J</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Safonov+A%22">Safonov A</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bromberg+M%22">Bromberg M</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ahmed+M%22">Ahmed M</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Razavi+P%22">Razavi P</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Jhaveri+K%22">Jhaveri K</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA. jhaverik@mskcc.org.; Weill Cornell Medical Center, New York, NY, USA. jhaverik@mskcc.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100927353%22">Breast cancer research : BCR</searchLink> [Breast Cancer Res] 2026 Jan 31; Vol. 28 (1). <i>Date of Electronic Publication: </i>2026 Jan 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Observational Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central+Ltd%22">BioMed Central Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100927353 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1465-542X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214655411%22">14655411 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41620612
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13058-025-02152-0
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shen S
      – PersonEntity:
          Name:
            NameFull: Teysir J
      – PersonEntity:
          Name:
            NameFull: Safonov A
      – PersonEntity:
          Name:
            NameFull: Bromberg M
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Ahmed M
      – PersonEntity:
          Name:
            NameFull: Razavi P
      – PersonEntity:
          Name:
            NameFull: Jhaveri K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 01
              Text: 2026 Jan 31
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1465-542X
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Breast cancer research : BCR
              Type: main
ResultId 1